Nivolumab in combination with azacitidine in patients with relapsed acute myeloid leukemia (AML)
Naval G. Daver
FLT3 inhibitors - their role in AML
AML17 trial update: FLT3-ITD mutation and daunorubicin dosage
Recognizing clonal hematopoiesis – diagnostic challenges and clinical relevance
Do Philadelphia chromosome-positive ALL patients need a stem cell transplant?